Researchers from the University of York elaborated in 2003 a paper on the benefits of parallel trade for patients and taxpayers. They estimated the direct savings for five countries (UK, Germany, Sweden, Netherlands and Denmark) in 2002 added up to €635 million. Evidence of competitive effects bringing prices of the medicines down in these countries was found, although indirect savings were not estimated in the paper.